News Releases - NervGen Pharma
Aug 27, 2024 — NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord …
News Releases Archives - NervGen Pharma
Aug 22, 2024 — Peptide Promotes Nervous System Repair in Stroke Animal Models. Read about NervGen in this article in Genetic Engineering and Biotechnology News. Read more.
NervGen Pharma Receives Fast Track Designation for NVG-291 …
NervGen has initiated a Phase 1b/2a placebo-controlled proof-of-concept trial (NCT05965700) to evaluate the efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal …
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of …
Jun 25, 2024 — "We are excited to advance NVG-300 toward development based on promising efficacy observed in a model of SCI characterized by heightened severity of spinal cord …
NervGen Pharma Announces First Subject Dosed in Landmark …
Sep 25, 2023 — Vancouver, British Columbia-- (Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated …
NervGen Pharma Receives Fast Track Designation for NVG-291 …
Oct 23, 2023 — NGENF. Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs. Enrollment Progressing in NVG-291 Phase 1b/2a Clinical …
NervGen Pharma to Present Innovative Treatments - Markets Insider
4 days ago — NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 Healthcare Conference, highlighting its innovative treatments for nervous system repair. …
NervGen Pharma’s NVG-291-R Demonstrates Significant …
Jul 28, 2022 — NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple …
NervGen Pharma on Track to Complete Enrollment, Deliver Data …
Feb 15, 2024 — NervGen's lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The Company's initial target indication is spinal cord injury.
Homepage - NervGen Pharma
Sep 30, 2024 — News Release. NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury. September 30, 2024. NervGen announced that target …